# OnCo record luspatercept (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/luspatercept/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "luspatercept" ;
  schema:name "Luspatercept"@en ;
  schema:description "An injection that helps the marrow finish making red cells, reducing or removing the need for transfusions in lower-risk MDS and beta-thalassaemia."@en ;
  schema:url <https://onco.cc/drugs/luspatercept/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Luspatercept> ;
  owl:sameAs <http://www.wikidata.org/entity/Q30314143> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(23)00874-7>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=luspatercept> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Erythroid maturation agent (activin receptor IIB ligand trap, Fc fusion)" ;
  schema:alternateName "Reblozyl" ;
  onco:approval "US 2019: Beta-thalassaemia transfusion-dependent anaemia", "US 2020: Very low- to intermediate-risk MDS with ring sideroblasts after ESA failure", "US 2023: First-line anaemia in ESA-naive lower-risk MDS", "EU 2020: MDS-RS and beta-thalassaemia" ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/mds-lower-risk/> ;
  onco:technologies <https://onco.cc/technologies/transfusion-support/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct04717414/>, <https://onco.cc/trials/nct04064060/> .